Effectiveness and Safety of Adjunctive Cenobamate in People with Focal-Onset Epilepsy: Evidence from the First Interim Analysis of the BLESS Study
-
Published:2024-06-08
Issue:4
Volume:13
Page:1203-1217
-
ISSN:2193-8253
-
Container-title:Neurology and Therapy
-
language:en
-
Short-container-title:Neurol Ther
Author:
Lattanzi SimonaORCID, Ranzato Federica, Di Bonaventura Carlo, Bonanni Paolo, Gambardella Antonio, Tartara Elena, Assenza Giovanni, Procaccini Michela, Falsetto Nathalie, Villano Valentina, Camattari Gabriele, Ori Alessandra, Di Gennaro Giancarlo, , D’Aniello Alfredo, Catania Cecilia, Morano Alessandra, Orlando Biagio, La Neve Angela, Francavilla Teresa, Mazzeo Francesca Pia, Pauletto Giada, Belluzzo Marco, Nilo Anna Carmen, Peretti Alessia, Polo Diana, Lippa Giulia, Nesta Marianna, Ricci Lorenzo, Danieli Alberto, Osanni Elisa, Fortunato Francesco, Magro Giuseppe, Marino Laura, Sammarra Ilaria, Galimberti Carlo Andrea, Lomonaco Domenico, Pignatta Pietro, Collura Devis, Viglietta Emanuela
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Ioannou P, Foster DL, Sander JW, et al. The burden of epilepsy and unmet need in people with focal seizures. Brain Behav. 2022;12(9): e2589. 2. Elizebath R, Zhang E, Coe P, Gutierrez EG, Yang J, Krauss GL, Epilepsy Behav. Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment. 2021;116:107796 3. Asadi-Pooya AA, Brigo F, Lattanzi S, Blumcke I. Adult epilepsy. Lancet. 2023;402:412–24. 4. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279–86. 5. ONTOZRY® Summary of Product Characteristics_last update on January 2024
|
|